Evidence map›Paper›PMID 41460409›Full record

ReviewCurrent cardiology reports2025

Mesenchymal Stem Cell Based-Regenerative Therapy in Atherosclerosis: an Updated Review.

Hanie Mahaki, Mohsen Sheykhhasan, Hamid Reza Rahimi, Gholamhossein Kazemzadeh, Hassan Ravari, Sima Nobari, Hanieh Salmani Izadi, Susan Darroudi, Fatemeh Forouzanfar, Hamed Afkhami and 1 more

Abstract readReview
PubMed Publisher
In one paragraph

Review in Current cardiology reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Hanie MahakiVascular and Endovascular Surgery Research Center, Mashhad University of Medical Sciences, Mashhad, Iran.
Mohsen SheykhhasanCellular and Molecular Research Center, Qom University of Medical Sciences, Qom, Iran.
Hamid Reza RahimiVascular and Endovascular Surgery Research Center, Mashhad University of Medical Sciences, Mashhad, Iran.
Gholamhossein KazemzadehVascular and Endovascular Surgery Research Center, Mashhad University of Medical Sciences, Mashhad, Iran.
Hassan RavariVascular and Endovascular Surgery Research Center, Mashhad University of Medical Sciences, Mashhad, Iran.
Sima NobariGastroenterology and Liver Diseases Research Center, Research Institute for Gastroenterology and Liver Diseases, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
Hanieh Salmani IzadiResearch Committee, Mashhad University of Medical Sciences, Mashhad, Iran.
Susan DarroudiVascular and Endovascular Surgery Research Center, Mashhad University of Medical Sciences, Mashhad, Iran.
Fatemeh ForouzanfarDepartment of Neuroscience, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran.
Hamed AfkhamiCellular and Molecular Research Center, Qom University of Medical Sciences, Qom, Iran. hamedafkhami70@gmail.com.
Hamid TanzadehpanahAntimicrobial Resistance Research Center, Basic Science Research Institute, Mashhad University of Medical Sciences, Mashhad, Iran. h.tanzadehpanah@gmail.com.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purpose of reviewThe purpose of this review is to provide an updated overview of mesenchymal stem cell (MSC)-based regenerative therapies in atherosclerosis. We aim to explore the mechanisms, recent advancements, and challenges associated with MSC applications in treating atherosclerosis. RECENT

findingsRecent studies highlight the potential of MSCs in modulating inflammation, promoting vascular repair, and reducing plaque formation in atherosclerosis. Novel approaches, such as hypoxia-conditioned MSCs and combination therapies with biomaterials, have shown promising results in preclinical models. This review concludes that MSC-based therapies hold significant promise for treating atherosclerosis, but further clinical trials are needed to validate their safety and efficacy. Future research should focus on optimizing MSC delivery methods and understanding long-term outcomes.

Indexed as

AtherosclerosisMesenchymal Stem CellsMesenchymal Stem Cell TransplantationRegenerative MedicineHumansAtherosclerosisCardiovascular diseaseDifferentiation, endothelial cellMesenchymal stem cellTherapy

Identifiers

PMID41460409

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.